MedTrace Logo

Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score

NCT07681583 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-07-02

No results posted yet for this study

Summary

The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.

The study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.

The derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.

Conditions

  • Pneumonia
  • Fungal Pneumonia
  • Aspergillosis Pneumonia
  • Pulmonary Aspergillosis
  • Pulmonary Aspergillosis Invasive
  • Pneumocystis
  • Pneumocystis Pneumonia
  • Fungal Disease
  • Fungal Infection
  • Fungal Infection Lungs

Interventions

OTHER

FUNGAL-P Score Assessment

Observational assessment of clinical, laboratory, radiological, and microbiological variables used to derive and validate the FUNGAL-P clinical prediction score for fungal pneumonia. No study-specific intervention was performed and patient management was not influenced by the study.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Careggi

    lead OTHER

Principal Investigators

  • Lorenzo Pelagatti, MD, PhD · University of Florence

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2030-11-13
Completion
2031-11-13

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07681583 on ClinicalTrials.gov